Methods for affinity maturation-based antibody optimization

• US 10,101,333 B2
• Filed: 04/21/2015
• Issued: 10/16/2018
• Est. Priority Date: 11/04/2009
• Status: Active Grant

• Current Assignee: Taurus Biosciences LLC (Ligand Pharmaceuticals, Inc.)
• Original Assignee: Taurus Biosciences, Inc.
• Inventors: Smider, Vaughn, Mao, Helen Hongyuan
• Primary Examiner(s): Boesen, Christian C
• Application Number:
  US14/692,646
• Publication Number:
  US 20160069894A1
• Time in Patent Office: 1,274 Days
• Field of Search: None
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 16/00 Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies antibodies with enzymatic activity, e.g. abzymes C12N9/0002
• CPC Class Codes: C07K 16/28 against receptors, cell surface antigens or cell surface determinants
• CPC Class Codes: C07K 16/2863 against receptors for growth factors, growth regulators
• CPC Class Codes: C07K 16/32 against translation products of oncogenes
• CPC Class Codes: C07K 2317/33 Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
• CPC Class Codes: C07K 2317/34 Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• CPC Class Codes: C07K 2317/55 Fab or Fab'
• CPC Class Codes: C07K 2317/56 variable (Fv) region, i.e. VH and/or VL
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C07K 2317/92 Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
• CPC Class Codes: C12N 15/1058 Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
• CPC Class Codes: C40B 30/04 by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
• CPC Class Codes: G01N 33/6845 Methods of identifying protein-protein interactions in protein mixtures

Abstract

Provided herein is a rational method of affinity maturation to evolve the activity of an antibody or portion thereof based on the structure/affinity or activity relationship of an antibody. The resulting affinity matured antibodies exhibit improved or optimized binding affinity for a target antigen.

Claims

1. A method of affinity maturation of a first antibody for a target antigen, comprising:

a) identifying a related antibody that exhibits a reduced affinity for the target antigen than the corresponding form of a first antibody by screening a spatially addressable combinatorial antibody library, wherein the related antibody contains a related variable heavy chain or a related variable light chain that is either;

one in which the corresponding variable heavy chain and variable light chain of the related antibody exhibits at least 75% amino acid sequence identity to the corresponding variable heavy chain or variable light chain of the first antibody but does not exhibit 100% sequence identity therewith;

or

one in which at least one of the V_H, D_H, and J_H germline segments of a nucleic acid molecule encoding the variable heavy chain of the related antibody is from the same gene family as one of the V_H, D_H, and J_H germline segments of the nucleic acid molecule encoding the variable heavy chain of the first antibody and at least one of the V_κ

and J_κ

or at least one of the V_λ

and J_λ

germline segments of the nucleic acid molecule encoding the variable light chain is from the same gene family as to one of the V_κ

and J_κ

or V_λ

and J_λ

germline segments of the nucleic acid molecule encoding the variable light chain of the first antibody; and

b) comparing the amino acid sequence of the variable heavy chain or variable light chain of the first antibody to the amino acid sequence of the corresponding related variable heavy chain or variable light chain of the related antibody;

c) identifying a target region within the variable heavy chain or variable light chain of a first antibody wherein the target region exhibits at least one amino acid difference compared to the same region in the related antibody;

d) producing a plurality of modified antibodies each comprising a variable heavy chain and a variable light chain wherein at least one of the variable heavy chain or variable light chain is modified in its target region by replacement of a single amino acid residue, whereby the target region in each of the plurality of antibodies contains replacement of an amino acid to a different amino acid compared to the first antibody;

e) screening each of the plurality of modified antibodies for an affinity to the target antigen; and

f) selecting those modified antibodies that exhibit increased affinity for the target antigen compared to the first antibody.

2. A method according to claim 1, wherein the plurality of modified antibodies in part (d) are produced by producing a plurality of nucleic acid molecules that encode modified forms of a variable heavy chain or a variable light chain of the first antibody, wherein the nucleic acid molecules contain one codon encoding an amino acid in the target region that encodes a different amino acid as compared to the unmodified variable heavy or variable light chain, whereby each nucleic acid molecule of the plurality encodes a variable heavy chain or variable light chain that is modified in its target region by replacement of a single amino acid residue.

3. A method according to claim 1, wherein the variable heavy chain or variable light chain of the first antibody exhibits at least 75% or more sequence identity with the corresponding related variable heavy chain or variable light chain of the related antibody;

75% to 99% of the sequence identity with the corresponding related variable heavy chain or variable light chain of the related antibody, or at least or about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, sequence identity with the corresponding related variable heavy chain or variable light chain of the related antibody.

4. A method according to claim 1, wherein the target region is selected from the group consisting of a CDR1, CDR2, CDR3, FR1, FR2, FR3, and FR4.

5. A method according to claim 1, wherein:

a) the first antibody is identified by screening a spatially addressable combinatorial antibody library or spatially addressable combinatorial antigen-binding antibody fragment library;

b) the spatially addressable combinatorial library is produced by a method comprising;

i) combining a V_H, a D_H, and a J_H human germline segment or portion thereof in frame to generate a sequence of a nucleic acid molecule encoding a VH chain;

ii) combining a V_κ

and a J_κ

human germline segment or portion thereof, or a V_λ

and a J_λ

germline segment or portion thereof in frame to generate a sequence of a nucleic acid molecule encoding a VL chain, wherein;

in steps i) and ii), each of the portions of the V_H, D_H, J_H, V_κ

, J_κ

, V_λ

or J_λ

are sufficient to produce an antibody containing a VH or VL that forms a sufficient antigen binding site;

iii) repeating steps i) and ii) a plurality of times to generate sequences of a plurality of different nucleic acid molecules;

iv) synthesizing the nucleic acid molecules to produce two libraries, wherein;

the first library comprises nucleic acid molecules encoding a VH chain; and

the second library comprises nucleic acid molecules encoding a VL chain;

v) introducing a nucleic acid molecule from the first library and from the second library into a cell and repeating this a plurality of times to produce a library of cells, wherein each cell contains nucleic acid molecules encoding a different combination of VH and VL from at least some of the other cells in the library of cells; and

vi) growing the cells to express the antibodies thereby producing a plurality of antibodies, wherein the different antibodies in the library each comprise a different combination of a VH and a VL chain to form an antigen binding site; and

c) screening of the library is effected by;

i) contacting an antibody in the library with a target protein;

ii) assessing binding of the antibody with the target protein and/or whether the antibody modulates a functional activity of the target protein; and

iii) identifying an antibody that exhibits an affinity for the target protein, wherein the identified antibody is a first antibody.

6. A method according to claim 5 that further includes at least one of the following:

a) the related antibody also is identified by screening a spatially addressable combinatorial antibody library by steps a)-c), whereby the related antibody exhibits reduced activity for the target antigen compared to the first antibody;

b) the library is a spatially addressable library, whereby;

in step iv), the synthesized nucleic acid sequences are individually addressed, thereby generating a first addressed nucleic acid library and a second addressed nucleic acid library;

in step v), the cells are addressed, wherein each locus comprises a cell that contains nucleic acid molecules encoding a different combination of a VH and a VL from every other cell in the addressed library of cells; and

in step vi) the plurality of antibodies are addressed, wherein;

the antibodies at each locus in the library are the same antibody and are different from those at each and every other locus;

and the identity of the antibody is known by its address, wherein optionally the antibodies in the addressable library are arranged in a spatial array, optionally a multiwell plate, wherein each individual locus of the array corresponds to a different antibody member;

c) wherein the antibodies are in an addressable library, wherein optionally the antibodies in the addressable library are arranged in a spatial array, optionally a multiwell plate, wherein optionally each individual locus of the array corresponds to a different antibody member are attached to a solid support selected from the group consisting of a filter, chip, slide, bead or cellulose, and the different antibody members are immobilized to the surface thereof;

d) wherein the plurality of nucleic acid molecules are generated by a method selected from the group consisting of PCR mutagenesis, cassette mutagenesis, site-directed mutagenesis, random point mutagenesis, mutagenesis using uracil containing templates, oligonucleotide-directed mutagenesis, phosphorothioate-modified DNA mutagenesis, mutagenesis using gapped duplex DNA, point mismatch repair, mutagenesis using repair-deficient hast strains, restriction-selection and restriction-purification, deletion mutagenesis, mutagenesis by total gene synthesis, and double-strand break repair;

or

e) wherein the plurality of nucleic acid molecules are generated by a method selected from the group consisting of NNK, NNS, NNN, NNY, or NNR mutagenesis.

7. A method according to claim 1, further comprising before step d),

g) performing scanning mutagenesis of the first antibody comprising producing a plurality of modified antibodies comprising a variable heavy chain and a variable light chain, wherein at least one of the variable heavy chain or variable light chain is one that is modified by replacement of a single amino acid residue with a scanned amino acid residue in the target region, whereby each of the plurality of antibodies contains replacement of an amino acid in the target region compared to the first antibody, wherein the scanned amino acid optionally is selected from the group consisting of alanine, threonine, proline, glycine, and a non-natural amino acid;

h) screening each of the plurality of modified antibodies for an affinity to the target antigen; and

i) selecting a second antibody from among the modified antibodies that exhibits retained or increased affinity for the target antigen compared to the first antibody not containing the amino acid replacement, whereby the second antibody is used in place of the first antibody in step b).

8. A method according to claim 7 that further includes at least one of the following:

a) wherein the plurality of modified antibodies in step g) are produced by producing a plurality of nucleic acid molecules that encode modified forms of a variable heavy chain or a variable light chain of the first antibody containing the target region, wherein the nucleic acid molecules contain one codon that encodes a scanned amino acid in the target region compared to the corresponding codon of the unmodified variable heavy or variable light chain that does not encode the scanned amino acid, whereby each nucleic acid molecule of the plurality encodes a variable heavy chain or variable light chain that is modified by replacement of a single amino acid residue to the same scanned amino acid residue in the target region;

b) wherein a second antibody is selected that exhibits an affinity that is at least 75% or more of the affinity of the corresponding form of the first antibody;

is at least 75% to 200% of the affinity of the corresponding form of the first antibody;

or is at least or about 75%, 80%, 85%, 90%, 95%, 100%, 105%, 110%, 115%, 120%, 130%, 140%, 150%, 200% or more of the affinity of the corresponding form of the first antibody;

c) further comprising after step i) determining the amino acid residue position that is modified in the second antibody to contain a neutral amino acid compared to the first antibody not containing the amino acid replacement;

d) wherein a subset of the amino acid residues in the target region are modified by amino acid replacement to a scanned amino acid;

e) wherein only the amino acid residues that differ between the first antibody and related antibody in the target region are modified by amino acid replacement to a scanned amino acid;

f) wherein all of the amino acids in the target region are modified by amino acid replacement to a scanned amino acid;

g) wherein the selected modified antibody exhibits about 2-fold, 5-fold, 10-fold, 100-fold, 200-fold, 300-fold, 400-fold, 500-fold, 600-fold, 700-fold, 800-fold, 900-fold, 1000-fold, 2000-fold, 3000-fold, 4000-fold, 5000-fold, 10000-fold, or more improved activity for the target antigen compared to the first antibody;

or

h) wherein the modified antibody exhibits a binding affinity that is greater than the binding affinity of the first antibody and is about 1×

10<sup>−

9</sup>M or less;

1×

10<sup>−

9</sup>M to 1×

10<sup>−

11</sup> M;

or is or is about 1×

10<sup>−

9</sup> M, 2×

10<sup>−

9</sup> M, 3×

10<sup>−

9</sup> M, 4×

10<sup>−

9</sup> M, 5×

10<sup>−

9</sup> M, 6×

10<sup>−

9</sup> M, 7×

10<sup>−

9</sup> M, 8×

10<sup>−

9</sup> M, 9×

10<sup>−

9</sup> M, 1×

10<sup>−

10</sup> M, 2×

10<sup>−

10</sup> M, 3×

10<sup>−

10</sup> M, 4×

10<sup>−

10</sup> M, 5×

10<sup>−

10</sup> M, 6×

10<sup>−

10</sup> M, 7×

10<sup>−

10</sup> M, 8×

10<sup>−

10</sup> M, 9×

10<sup>−

10</sup> M, or less.

9. A method according to claim 1, comprising:

performing steps a)-f) on the variable heavy chain of the first antibody and selecting first modified antibodies each containing an amino acid replacement in the target region;

performing steps a)-f) independently and separately on the variable light chain of the first antibody and selecting second modified antibodies each containing an amino acid replacement in the target region;

combining the variable heavy chain of a first modified antibody with the variable light chain of a second modified antibody to generate a plurality of different third modified antibodies each comprising an amino acid replacement in the target region of the variable heavy chain and variable light chain; and

screening each of the plurality of third modified antibodies for binding to the target antigen; and

selecting those third modified antibodies that exhibit an increased affinity for the target antigen compared to the first and second modified antibodies.

10. A method according to claim 1, further comprising after selecting a first modified antibody in step f):

j) selecting another different region within the variable heavy chain or variable light chain of the first modified antibody for further mutagenesis, wherein optionally the further different region is selected from the group consisting of a CDR1, CDR2, CDR3, FR1, FR2, FR3, and FR4;

k) producing a plurality of nucleic acid molecules that encode modified forms of the variable heavy chain or variable light chain of the first modified antibody, wherein the nucleic acid molecules contain one codon encoding an amino acid in the selected region that encodes a different amino acid from the first modified variable heavy or variable light chain, whereby each nucleic acid molecule of the plurality encodes a variable heavy chain or variable light chain that is modified in the selected region by replacement of a single amino acid residue;

l) producing a plurality of further modified antibodies each comprising a variable heavy chain and a variable light chain, wherein at least one of the variable heavy chain or variable light chain is one produced in step k), whereby the selected region in each of the plurality of antibodies contains replacement of an amino acid to a different amino acid compared to the first modified antibody;

m) screening each of the plurality of further modified antibodies for binding to the target antigen; and

n) selecting those further modified antibodies that exhibit increased affinity for the target antigen compared to the first modified antibody.

11. A method according to claim 1, wherein the target region in the first antibody exhibits 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid differences compared to the corresponding region in the related antibody.

12. A method according to claim 1, wherein the related antibody is 1, 2, 3, 4, or 5 related antibodies.

13. A method according to claim 1, wherein the affinity is assessed by a method selected from the group consisting of an immunoassay, optionally an immunoassay selected from the group consisting of a radioimmunoassay, an enzyme linked immunosorbent assay (ELISA), and an electrochemiluminescence assay, wherein the electrochemiluminescence assay optionally is meso-scale discovery (MSD);

whole cell panning; and

surface Plasmon resonance (SPR).

14. A method according to claim 1, wherein the first antibody binds to the target antigen when in a Fab form with a binding affinity that is about 10⁻

4 M or lower, about 10<sup>−

4</sup> M to about 10<sup>−

8</sup> M, or at or about 10<sup>−

4</sup> M, 10<sup>−

5</sup> M, 10<sup>−

6</sup> M, 10<sup>−

7</sup> M, 10<sup>−

8</sup> M, or lower.

15. A method according to claim 1, wherein the related antibody exhibits a binding affinity that is less than the binding affinity of the first antibody, or antigen-binding portion thereof, whereby the binding affinity of the related antibody in its Fab form is about 10⁻

4 M or lower;

about 10<sup>−

4</sup> M to about 10<sup>−

8</sup> M;

or at or about 10<sup>−

4</sup> M, 10<sup>−

5</sup> M, 10<sup>−

6</sup> M, 10<sup>−

7</sup> M, 10<sup>−

8</sup> M, or lower.

16. A method according to claim 1, wherein the related antibody exhibits about 80% or less affinity than the corresponding form of the first antibody about 5% to about 80% of the affinity of the corresponding form of the first antibody;

or less than or about 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, 5%, or less affinity than the corresponding form of the first antibody.

17. A method according to claim 1, wherein the related antibody exhibits the same or similar level of affinity to the target antigen compared to a negative control.

18. A method according to claim 1, wherein the target region is identified within the variable heavy chain of the first antibody and steps d)-f) are performed therefrom.

19. A method according to claim 1, wherein the target region is identified within the variable light chain of the first antibody and steps d)-f) are performed therefrom.

20. A method according to claim 1, wherein a target region is identified within the variable heavy chain of the first antibody and steps d)-f) are performed therefrom;

and

separately and independently a target region is identified within the variable light chain of the first antibody and steps d)-f) are performed therefrom.

21. A method according to claim 1, wherein a related antibody that contains the related corresponding variable heavy chain is different than a related antibody that contains the related corresponding variable light chain.

22. A method according to claim 1, wherein a related antibody that contains the related corresponding variable heavy chain is the same as a related antibody that contains the related corresponding variable light chain.

23. A method according to claim 1, wherein the amino acid sequence of the variable heavy chain or variable light chain of the first antibody exhibits at least about 80% or more sequence identity with the corresponding amino acid sequence of the related variable heavy chain or variable light chain of the related antibody;

about 80% to about 99% of the sequence identity with the corresponding amino acid sequence of the related variable heavy chain or variable light chain of the related antibody;

or at least or about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with the corresponding amino acid sequence of the related variable heavy chain or variable light chain of the related antibody.

24. A method according to claim 1, wherein the variable heavy chain or variable light chain of the first antibody exhibits at least about 95% sequence identity with the corresponding amino acid sequence of the related variable heavy chain or variable light chain of the related antibody.

25. A method according to claim 1, wherein the related antibody contains a related variable heavy chain or variable light chain that is one in which at least one of the V_H, D_H, and J_H germline segments of the nucleic acid molecule encoding the variable heavy chain of the first antibody is identical to one of the V_H, D_H, and J_H germline segments of the nucleic acid molecule encoding the variable heavy chain of the related antibody;

and at least one of the V_κ

and J_κ

or at least one of the V_λ

and J_λ

germline segments of the nucleic acid molecule encoding the variable light chain of the first antibody is identical to one of the V_κ

and J_κ

or V_λ

and J_λ

germline segments of the nucleic acid molecule encoding the variable light chain of the related antibody.

26. A method according to claim 1, wherein the target antigen is selected from the group consisting of a polypeptide, carbohydrate, lipid, nucleic acid, and a small molecule.

27. A method according to claim 1, wherein the target antigen is expressed on the surface of a virus, bacteria, tumor or other cell, or is a recombinant protein or peptide.

28. A method according to claim 1, wherein the target antigen is a protein that is a target for therapeutic intervention, optionally selected from the group consisting of VEGFR-1, VEGFR-2, VEGFR-3 (vascular endothelial growth factor receptors 1, 2, and 3), a epidermal growth factor receptor (EGFR), ErbB-2, ErbB-3, IGF-R1, C-Met (also known as hepatocyte growth factor receptor;

HGFR), DLL4, DDR1 (discoidin domain receptor), KIT (receptor for c-kit), FGFR1, FGFR2, FGFR4 (fibroblast growth factor receptors 1, 2, and

     4), RON (recepteur d′

origine nantais;

also known as macrophage stimulating 1 receptor), TEK (endothelial-specific receptor tyrosine kinase), TIE (tyrosine kinase with immunoglobulin and epidermal growth factor homology domains receptor), CSF1 R (colony stimulating factor 1 receptor), PDGFRB (platelet-derived growth factor receptor B), EPHA1, EPHA2, EPHB1 (erythropoietin-producing hepatocellular receptor A1, A2 and B1), TNF-R1, TNF-R2, HVEM, LT-β

R, CD20, CD3, CD25, NOTCH, G-CSF-R, GM-CSF-R, EPOR, a cadherin, an integrin, CD52, CD44, VEGF-A, VEGF-B, VEGF-C, VEGF-D, PIGF, EGF, HGF, TNF-α

, LIGHT, BTLA, lymphotoxin (LT), lgE, G-CSF, GM-CSF and EPO.

29. A method according to claim 1, wherein the target antigen is involved in cell proliferation and differentiation, cell migration, apoptosis or angiogenesis.

30. A method according to claim 1, wherein a subset of the amino acid residues in the target region are modified by amino acid replacement.

31. A method according to claim 1, wherein only the amino acid residues that differ between the first antibody and related antibody in the target region are modified by amino acid replacement.

32. A method according to claim 1, wherein only the amino acid residues that are the same between the first antibody and the related antibody in the target region are modified by amino acid replacement.

33. A method according to claim 1, wherein all of the amino acids residues in the target region are modified by amino acid replacement.

34. A method according to claim 1, wherein each amino acid residue that is modified in the target region is modified to all 19 other amino acid residues, or a restricted subset thereof.

35. A method according to claim 1, further comprising determining the amino acid modifications that are altered in the modified antibody compared to the first antibody not containing the amino acid replacements.

36. A method according to claim 1, wherein the method is repeated iteratively, and wherein a modified antibody is selected and used in step a) as the first antibody for subsequent affinity maturation thereof.

37. A method according to claim 1, wherein one or more amino acid replacements in the target region of one or more variable heavy chains or one or more variable light chains of selected modified antibodies are combined to generate a further modified antibody, whereby the further modified antibody(ies) are screened for an affinity to the target antigen to identify a further modified antibody that exhibits an increased affinity for the target antigen compared to the first antibody and to the selected modified antibody(ies).

38. A method according to claim 1, wherein the antibody comprising a variable heavy chain and a variable light chain is selected from the group consisting of a Fab, Fab′

, F(ab′

)2, single-chain Fv (scFv), scFab, Fv, dsFv, diabody, Fd, Fd′

, Fab fragment, Fd fragment, Fd′

fragment, scFv fragment, and scFab fragment.